Aligos Therapeutics reported that dosing with ALG-125755, a small interfering RNA targeting the production of hepatitis B surface antigen, or HBsAg, was initiated in subjects with chronic hepatitis B, or CHB, in Study ALG-125755-501.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALGS:
- Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)
- Aligos presents nonclinical data for coronavirus therapeutic program
- Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022
- Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
- Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA